t to the collaboration agreement, Allergan paid the Company an upfront payment of $60.0 million, $34.2 million of which was recognized as collaboration revenue in the quarter ended March 31, 2011. The remaining $25.8 million is deferred revenue and will be amortized as collaboration revenue over the estimated obligation periods. Under the terms of the collaboration agreement, the Company may also receive up to an additional $97.0 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the LEVADEX NDA and first commercial sale associated with the initial acute migraine indication.
Research and development (R&D) expenses for the first quarter ended March 31, 2011 were $11.6 million compared to $9.8 million for the same period in 2010. The increase in R&D expenses for the first quarter ended March 31, 2011 was driven primarily by an increase in expenses related to the LEVADEX program, including a milestone of $1.0 million paid by the Company to a third party licensor as a result of entering into the Allergan collaboration, and an increase in personnel related expenses, including stock-based compensation.
Sales, general and administrative (SG&A) expenses for the first quarter ended March 31, 2011 were $4.8 million compared to $3.9 million for the same period in 2010. The increase in SG&A expenses was related primarily to increases in personnel related expenses, including stock-based compensation and professional services.
For the first quarter ended March 31, 2011, non-cash stock-based compensation and depreciation expense was approximately $2.4 million.
2011 Financial Outlook
MAP Pharmaceuticals' financial outlook is based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements."
The Company currently anticipates
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT2
. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results3
. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 20084
. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results5
. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist6
. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference7
. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman8
. Access Pharmaceuticals to Present at the Noble Financial Equity Conference9
. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)10
. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition11
. Lotus Pharmaceuticals Announces Second Quarter 2008 Results